DPX E7

Drug Profile

DPX E7

Alternative Names: DPX-E7; HPV16-E711-19

Latest Information Update: 11 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Immunovaccine
  • Developer Dana-Farber Cancer Institute; Immunovaccine; Peregrine Pharmaceuticals
  • Class Cancer vaccines; Viral vaccines
  • Mechanism of Action Human papillomavirus E7 protein modulators; Viral oncogene protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Anal cancer; Cervical cancer; Head and neck cancer
  • Preclinical Solid tumours

Most Recent Events

  • 11 Apr 2017 Pharmacodynamics data from the preclinical trials presented at the American Association for Cancer Research annual meeting 2017 (AACR-2017)
  • 24 Mar 2017 Preclinical trials in Solid tumours (Combination therapy) in USA (unspecified route)
  • 21 Oct 2016 Phase-I/II clinical trials in Anal cancer, Cervical cancer and Head and neck cancer (Combination therapy) in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top